Indivior Announces Completion of London Delisting

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange;
Primary Listing on Nasdaq to be Maintained
Indivior has prepared an FAQ document for shareholders in connection with the London Delisting, which is available at https://www.indivior.com/en/investors/shareholder-information.
About Indivior
Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in
Media Contacts:
Cassie
Vice President, Communications
Indivior PLC
Tel: 804-724-0327
Investor Contacts:
Jason Thompson
Vice President, Investor Relations
Tel: 804-402-7123
jason.thompson@indivior.com
Tim Owens
Director, Investor Relations
Tel: 804-263-3978
timothy.owens@indivior.com
-ends-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCUSAORVKUBUAR